Save time and jump to the most important pieces.
4 - POLARITYTE, INC. (0001076682) (Issuer)
3 - POLARITYTE, INC. (0001076682) (Issuer)
4 - POLARITYTE, INC. (0001076682) (Issuer)
8-K - POLARITYTE, INC. (0001076682) (Filer)
NT 10-Q - POLARITYTE, INC. (0001076682) (Filer)
8-K - POLARITYTE, INC. (0001076682) (Filer)
PolarityTE to host conference call and webcast today, August 11, 2022, at 4:30 p.m. ET SALT LAKE CITY, Aug. 11, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended June 30, 2022. Recent Business and Financial UpdatesIn January 2022, PolarityTE was advised by the U.S. Food and Drug Administration (FDA) that it could conduct human clinical trials under PolarityTE's investigational new drug application (IND
SALT LAKE CITY, Aug. 1, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on August 11, 2022, at 4:30 p.m. Eastern Time. The conference call can be accessed by calling 1-800-207-0148 with passcode 893469 and referencing "PolarityTE Second Quarter 2022 Business Update and Financial Results." A webcast of the conference call can be accesse
Dr. Josh Packer acquires IBEX and becomes CEO; maintains existing surgical research team LOGAN, Utah, May 26, 2022 /PRNewswire-PRWeb/ -- IBEX Preclinical Research, Inc., a trusted outsourcing partner and provider of preclinical surgical and toxicological studies in a variety of laboratory animal species, announced that it has been acquired by Josh Packer, DVM. IBEX provides in-vivo research services ranging from relatively simple single-dose pharmacokinetic studies to more complex projects requiring surgical instrumentation. Conducting both GLP and non-GLP non-clinical testing, IBEX supports life science, medical device companies and researchers that specialize in orthopedics, neurosurgical,
SALT LAKE CITY, Dec. 27, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials (the "Company"), today announced that it signed a non-binding letter of intent (the "LOI") with Michael Brauser ("Brauser") for him to make an offer to acquire 100% of the outstanding equity interests of the Company at a proposed offering price of $1.03 per common share, which would be paid entirely in cash. As of December 23, 2022, there were 7,256,786 shares of the Company's common stock outstanding and unvested restricted stock units covering an additional 256,457 common shares.
SALT LAKE CITY, Nov. 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended September 30, 2022. Recent Business and Financial UpdatesAt the end of April 2022, PolarityTE began enrollment in its Phase III randomized controlled trial (RCT), which is a pivotal study under its open IND for SkinTE®. The Company estimates that it may be able to complete enrollment of 100 subjects sometime in the first six mon
SALT LAKE CITY, Nov. 9, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, today confirmed that on November 1, 2022, it received an unsolicited, non-binding offer (followed by an amended offer on November 8, 2022) from Michael Brauser to acquire all of the outstanding common stock of the Company not owned by him for $1.25 per share in cash. The offer is subject to various contingencies, including, among others, (1) settlement with warrant holders and satisfactory negotiations with insiders with change of control agreements, (2) minimum tender conditions, (3) a sixty-day due diligence period, and (4) satisfacti
SC 13G/A - POLARITYTE, INC. (0001076682) (Subject)
SC 13G - POLARITYTE, INC. (0001076682) (Subject)
SC 13G - POLARITYTE, INC. (0001076682) (Subject)
SALT LAKE CITY, Sept. 8, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately. "On behalf of our Board and PolarityTE's management team, we thank Jeff for his service and longstanding commitment to the Company," stated Richard Hague, Chief Executive Officer of PolarityTE. "We greatly appreciate the leadership and insight that Jeff has provided over the past five and a half years as we purs
SAN DIEGO--(BUSINESS WIRE)--Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra
Gainers EdtechX Holdings Acquisition Corp. II (NASDAQ:EDTX) shares gained 139.8% to $26.54 in pre-market trading. BitNile Metaverse, Inc. (NASDAQ:BNMV) shares surged 38.5% to $1.80 in pre-market trading. BitNile.com said it has begun generating revenue from social gaming and Metaverse ads. Leju Holdings Limited (NYSE:LEJU) shares rose 37% to $4.00 in pre-market trading after gaining 15% on Wednesday. PolarityTE, Inc. (NASDAQ:PTE) shares rose 33.3% to $0.3240 in pre-market trading. MicroVision, Inc. (NASDAQ:MVIS) gained 27.8% to $5.88 in pre-market trading. MicroVision reported withdrawal of public offering of common stock. Nikola Corporation (NASDAQ:NKLA) gained 19.4% to $1.29 in pr
Gainers First Wave BioPharma (NASDAQ:FWBI) stock rose 136.5% to $2.7 during Tuesday's pre-market session. The company's market cap stands at $5.2 million. YS Biopharma Co (NASDAQ:YS) shares rose 41.93% to $1.76. The market value of their outstanding shares is at $163.7 million. iBio (AMEX:IBIO) stock rose 20.79% to $0.88. The market value of their outstanding shares is at $14.7 million. SILO Pharma (NASDAQ:SILO) shares increased by 19.17% to $2.83. The company's market cap stands at $8.9 million. PolarityTE (NASDAQ:PTE) stock increased by 13.94% to $0.23. The market value of their outstanding shares is at $1.6 million. Journey Medical (NASDAQ:DERM) shares moved upwards by 13.77% to $1.
Gainers YS Biopharma Co., Ltd. (NASDAQ:YS) shares rose 90.3% to $2.36 in pre-market trading after dropping over 7% on Monday. YS Biopharma's PIKA Rabies Vaccine recently received Phase 3 clinical trial approval from Philippines FDA. The OLB Group, Inc. (NASDAQ:OLB) shares surged 61.2% to $1.08 in pre-market trading. The company, last month, posted downbeat quarterly results. iBio, Inc. (NYSE:IBIO) shares gained 31.4% to $0.9581 in pre-market trading. iBio reported a research collaboration with NIH to investigate potential of company's AI-driven epitope steering platform for lassa fever vaccine development. SunCar Technology Group Inc. (NASDAQ:SDA) gained 31.2% to $22.13 in pre-market